Fulgent Genetics, Inc. (FLGT)

In the past six months, Fulgent Genetics announced preliminary data from a Phase 2 study of FID-007 and is scheduled to announce its Third Quarter 2025 Financial Results on November 7, 2025. The company announced its Q2 2025 earnings on August 1, 2025. UBS upgraded Fulgent Genetics to a "Buy" rating, while Piper Sandler gave it a "Hold" rating. There have been reports of insider trading, including an insider increasing their holding and top executives selling shares. The stock price fell by -1.81% on October 27, 2025, but has shown increases over the last six months and year.

Fulgent Genetics' Inform Diagnostics business experiences seasonality, with a drop in elective surgeries around the holiday season. The demand for genetic testing has been rising due to increased public awareness, direct-to-consumer test kits, and the growing prevalence of genetic disorders. Prenatal and preconception genetic testing also contributes to demand, and the global genetic testing market is projected to grow significantly.

Fulgent Genetics, Inc. is a technology-driven company specializing in genetic testing and diagnostics, as well as therapeutic development solutions, operating within the Healthcare sector. The company offers clinical diagnostic solutions, including hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, carrier screening, oncology testing, reproductive health services, newborn genetic analysis panels, whole genome and exome sequencing, infectious disease assays, and anatomic pathology laboratory tests. It also provides the Picture Genetics Platform, therapeutic development solutions focused on cancer treatment, and custom research services.

Fulgent Genetics, Inc. operates in the United States and internationally. Its headquarters are in El Monte, California, with other offices and laboratories across the United States. The company also has international subsidiaries in China and Hong Kong.

In the past year, Fulgent Genetics secured a five-year contract from the U.S. Department of Veterans Affairs and entered into a collaboration with Moffitt Cancer Center to advance cancer therapeutics. The company also introduced KNOVA prenatal cell-free DNA screening, demonstrating its continued innovation and expansion in the genetic testing and therapeutic fields.

Fulgent Genetics, Inc. has a significant portion of its stock held by institutional investors, with 48.06% held by institutions including BlackRock, Inc., Millennium Management Llc, and Vanguard Group Inc. Insiders hold 33.11% of the company's stock, with the CEO, Ming Hsieh, being a significant individual shareholder.